AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12047603 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg brotizolam (BR)
Number of subjects: 10
Study 12047603 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo (PL)
Number of subjects: 10
Study 10399200 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS prophylaxis
Number of subjects: 0
Study 10399200 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal measures
Number of subjects: 0
Study 7546753 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia with plain 1% lidocaine
Number of subjects: 20
Study 7546753 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia induction
Number of subjects: 20
Study 7546753 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia combined with general anesthesia
Number of subjects: 20
Study 2265259 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen (TM), 30 mg per day for 2 years
Number of subjects: 308
Study 2265259 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 308
Study 7417366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (5‐(6‐chlorobenzyl)‐4,5,6,7‐tetrahydrothieno‐(3,2‐C)‐pyridine HCl) for one or four months
Number of subjects: 12
Study 7417366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 12
Study 31426760 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) with doses of 20 Gy in 1 fraction, 30 Gy in 3 fractions, or 35 Gy in 5 fractions, completed within 2 weeks.
Number of subjects: 159
Study 31426760 — intervention group
Group type: COMPARATOR
Intervention: Standard of care palliative-intent treatments (Control group).
Number of subjects: 159
Study 28351963 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ischemic lesion volume (ILV) measured by noncontrast computed tomography
Number of subjects: 228
Study 28351963 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week ischemic lesion volume (ILV) measured by noncontrast computed tomography
Number of subjects: 228
Study 25862428 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume polyethylene glycol containing ascorbic acid (n = 31)
Number of subjects: 62
Study 25862428 — intervention group
Group type: COMPARATOR
Intervention: 2 L of polyethylene glycol plus bisacodyl (n = 31)
Number of subjects: 62
Study 24219197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (H-PRT)
Number of subjects: 22
Study 24219197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity nonprogressive resistance training (L-RT)
Number of subjects: 22
Study 24219197 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (unsupervised walking)
Number of subjects: 22
Study 21378213 — intervention group
Group type: EXPERIMENTAL
Intervention: Latinos en Control intervention
Number of subjects: 252
Study 21378213 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 252
Study 19627261 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time postural equipment (NTPE)
Number of subjects: 10
Study 19627261 — intervention group
Group type: COMPARATOR
Intervention: Sleeping unsupported
Number of subjects: 10
Study 19627261 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (children with severe CP)
Number of subjects: 10
Study 17276533 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) to the left breast
Number of subjects: 6680
Study 17276533 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior internal mammary node (IMC) RT
Number of subjects: 6680
Study 17276533 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior left breast boost RT
Number of subjects: 6680
Study 15067425 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagged MRI
Number of subjects: 28
Study 15067425 — intervention group
Group type: COMPARATOR
Intervention: Standard bright-blood cine MRI
Number of subjects: 28
Study 11698604 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaf signers
Number of subjects: 0
Study 11698604 — intervention group
Group type: COMPARATOR
Intervention: Hearing controls
Number of subjects: 0
Study 11698604 — intervention group
Group type: COMPARATOR
Intervention: Hearing native signers
Number of subjects: 0
Study 8975918 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-valent CRM-OS (10 micrograms of oligosaccharide per serotype)
Number of subjects: 99
Study 8975918 — intervention group
Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (PS) (25 micrograms of polysaccharide per serotype)
Number of subjects: 99
Study 8975918 — intervention group
Group type: EXPERIMENTAL
Intervention: CRM-OS followed by revaccination with PS at 2 months
Number of subjects: 99
Study 8975918 — intervention group
Group type: EXPERIMENTAL
Intervention: CRM-OS
Number of subjects: 99
Study 8975918 — intervention group
Group type: COMPARATOR
Intervention: PS
Number of subjects: 99
Study 7932517 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10-40 mg once daily
Number of subjects: 50
Study 7932517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3370923 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions at short length
Number of subjects: 8
Study 3370923 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions at long length
Number of subjects: 8
Study 29899643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab (IVB)
Number of subjects: 136
Study 29899643 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal Bevacizumab with Triamcinolone (IVB/IVTA)
Number of subjects: 136
Study 26950808 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Mixtatin
Number of subjects: 65
Study 26950808 — intervention group
Group type: COMPARATOR
Intervention: MTA
Number of subjects: 65
Study 25422235 — intervention group
Group type: EXPERIMENTAL
Intervention: Chongcao Yigan Capsule
Number of subjects: 136
Study 25422235 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (Control)
Number of subjects: 136
Study 22178506 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR Anytime™ self-learning kit (Rx for CPR kit)
Number of subjects: 162
Study 22178506 — intervention group
Group type: COMPARATOR
Intervention: CPR class (Rx for CPR class)
Number of subjects: 162
Study 19884368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 25 mg
Number of subjects: 56
Study 19884368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 50 mg
Number of subjects: 56
Study 19884368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 125 mg
Number of subjects: 56
Study 19884368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 250 mg
Number of subjects: 56
Study 19884368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg
Number of subjects: 56
Study 19884368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 1000 mg
Number of subjects: 56
Study 19884368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 1500 mg
Number of subjects: 56
Study 19884368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18804239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubovaginal sling surgery
Number of subjects: 655
Study 18804239 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 655
Study 18804239 — intervention group
Group type: COMPARATOR
Intervention: Preoperative urodynamic studies
Number of subjects: 655
Study 18804239 — intervention group
Group type: COMPARATOR
Intervention: Maximum flow during noninvasive flowmetry
Number of subjects: 655
Study 18804239 — intervention group
Group type: COMPARATOR
Intervention: Voiding pressures and degree of abdominal straining
Number of subjects: 655
Study 15660184 — intervention group
Group type: EXPERIMENTAL
Intervention: Paula method of circular muscle training
Number of subjects: 59
Study 15660184 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor training
Number of subjects: 59
Study 12094846 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 203
Study 12094846 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 203
Study 12094846 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg and 20 mg
Number of subjects: 203
Study 12094846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 10592838 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 20
Study 10592838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 7724891 — intervention group
Group type: COMPARATOR
Intervention: Morphine 2.5 mg i.v. on‐demand (Group 1)
Number of subjects: 85
Study 7724891 — intervention group
Group type: COMPARATOR
Intervention: Clonixin 400 mg/day i.v. infusion (Group 2)
Number of subjects: 85
Study 7724891 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.4 mg/kg/day i.v. infusion (Group 3)
Number of subjects: 85
Study 7724891 — intervention group
Group type: COMPARATOR
Intervention: Clonixin 400 mg/day plus morphine 0.4 mg/kg/day i.v. infusion (Group 4)
Number of subjects: 85
Study 1701005 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFO)
Number of subjects: 673
Study 1701005 — intervention group
Group type: COMPARATOR
Intervention: Conventional intermittent mechanical ventilation (IMV)
Number of subjects: 673
Study 6772386 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem, 240 mg daily dose
Number of subjects: 0
Study 6772386 — intervention group
Group type: COMPARATOR
Intervention: Long-acting vasodilators
Number of subjects: 0
Study 6772386 — intervention group
Group type: COMPARATOR
Intervention: Alpha-adrenergic blockade
Number of subjects: 0
Study 31490566 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based patient support tool
Number of subjects: 664
Study 31490566 — intervention group
Group type: COMPARATOR
Intervention: Control group without the patient support tool
Number of subjects: 664
Study 28076921 — intervention group
Group type: EXPERIMENTAL
Intervention: GWWFV with taste testing
Number of subjects: 747
Study 28076921 — intervention group
Group type: EXPERIMENTAL
Intervention: FFVSP
Number of subjects: 747
Study 28076921 — intervention group
Group type: COMPARATOR
Intervention: GWWFV without taste testing
Number of subjects: 747
Study 28076921 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 747
Study 27530339 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml of autologous bone marrow cells (BMCs) by local intramuscular application (n=32)
Number of subjects: 62
Study 27530339 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml of autologous bone marrow cells (BMCs) by intra-arterial application (n=30)
Number of subjects: 62
Study 27530339 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 62
Study 24383962 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin/fosfomycin (300/120 mg combination)
Number of subjects: 9
Study 24383962 — intervention group
Group type: COMPARATOR
Intervention: volume‐matched placebo
Number of subjects: 9
Study 22257664 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration: ICON‐pre‐product; DMG
Number of subjects: 39
Study 22257664 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing: Prime‐Bond‐NT; Dentsply
Number of subjects: 39
Study 22257664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 19686874 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression diagnosed by GPs
Number of subjects: 1751
Study 19686874 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity of somatoform, depressive, and anxiety disorders
Number of subjects: 1751
Study 19686874 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatoform/functional disorder only
Number of subjects: 1751
Study 17710839 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraid device
Number of subjects: 134
Study 17710839 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 134
Study 15447697 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin 400 mg, Magnesium 300 mg, Feverfew 100 mg
Number of subjects: 120
Study 15447697 — intervention group
Group type: COMPARATOR
Intervention: Placebo (25 mg riboflavin)
Number of subjects: 120
Study 11240597 — intervention group
Group type: EXPERIMENTAL
Intervention: IM Fosphenytoin (10 mg/kg)
Number of subjects: 0
Study 11240597 — intervention group
Group type: COMPARATOR
Intervention: IM Saline (up to 19.5 mL or 2 mL)
Number of subjects: 0
Study 9855446 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of influenza vaccine
Number of subjects: 28
Study 9855446 — intervention group
Group type: COMPARATOR
Intervention: Control (no vaccination)
Number of subjects: 28
Study 9855446 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of influenza vaccine (1994-1995 season)
Number of subjects: 28
Study 7863247 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily a.m.)
Number of subjects: 31
Study 7863247 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine (300 mg twice daily)
Number of subjects: 31
Study 2491802 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate accelerated from low to high at exercise onset
Number of subjects: 5
Study 2491802 — intervention group
Group type: COMPARATOR
Intervention: Heart rate held constant at low rate at exercise onset
Number of subjects: 5
Study 2491802 — intervention group
Group type: COMPARATOR
Intervention: Heart rate constrained at cessation of exercise
Number of subjects: 5
Study 2491802 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt decrease in heart rate at cessation of exercise
Number of subjects: 5
Study 791382 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal EMG biofeedback
Number of subjects: 18
Study 791382 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 18
Study 791382 — intervention group
Group type: COMPARATOR
Intervention: Placebo relaxation exercises
Number of subjects: 18
Study 31734510 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3 (nano-emulsion artificial tear containing CMC, glycerin, flaxseed oil, castor oil, and osmoprotectants)
Number of subjects: 242
Study 31734510 — intervention group
Group type: COMPARATOR
Intervention: ROA (artificial tear containing CMC, glycerin, and castor oil, without trehalose and flaxseed oil)
Number of subjects: 242
Study 31734510 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3
Number of subjects: 242
Study 31734510 — intervention group
Group type: COMPARATOR
Intervention: ROA
Number of subjects: 242
Study 31453958 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-Meno
Number of subjects: 71
Study 28961465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg
Number of subjects: 540
Study 28961465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg
Number of subjects: 540
Study 28961465 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 540
Study 28961465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (both doses)
Number of subjects: 540
Study 25587172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient music during pulmonary rehabilitation session
Number of subjects: 41
Study 25587172 — intervention group
Group type: COMPARATOR
Intervention: No ambient music during pulmonary rehabilitation session
Number of subjects: 41
Study 23485994 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional RT (3DRT)
Number of subjects: 253
Study 23485994 — intervention group
Group type: COMPARATOR
Intervention: 2-dimensional RT (2DRT)
Number of subjects: 253
Study 23485994 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based simulation and planning (3DRT)
Number of subjects: 253
Study 23485994 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 253
Study 21570643 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Number of subjects: 62
Study 21570643 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Number of subjects: 62
Study 17700646 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 (1 mg/day for 1 month, then 2 mg/day for 2 months)
Number of subjects: 15
Study 17700646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16484769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mug once daily
Number of subjects: 100
Study 16484769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15018290 — intervention group
Group type: EXPERIMENTAL
Intervention: ReliefBand (trained)
Number of subjects: 77
Study 15018290 — intervention group
Group type: COMPARATOR
Intervention: Acuband (untrained)
Number of subjects: 77
Study 15018290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 15018290 — intervention group
Group type: COMPARATOR
Intervention: ReliefBand (untrained)
Number of subjects: 77
Study 15018290 — intervention group
Group type: COMPARATOR
Intervention: Acuband (trained)
Number of subjects: 77
Study 10697374 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid composition (100 mg 3 times a day sublingually)
Number of subjects: 60
Study 10697374 — intervention group
Group type: EXPERIMENTAL
Intervention: Preductal (20 mg 3 times a day)
Number of subjects: 60
Study 10697374 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 60
Study 10756785 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 100
Study 10756785 — intervention group
Group type: EXPERIMENTAL
Intervention: paduden
Number of subjects: 100
Study 10756785 — intervention group
Group type: EXPERIMENTAL
Intervention: aspirin
Number of subjects: 100
Study 1527304 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-limited exercise test
Number of subjects: 202
Study 1527304 — intervention group
Group type: COMPARATOR
Intervention: Low level exercise test
Number of subjects: 202
Study 4075944 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24
Study 4075944 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 24
Study 31291793 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg lipoic acid (LA) once daily for 12 weeks
Number of subjects: 44
Study 31291793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 28360145 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand nicotine levels
Number of subjects: 25
Study 28360145 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cotinine levels
Number of subjects: 25
Study 28360145 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between hand nicotine and cotinine
Number of subjects: 25
Study 26004515 — intervention group
Group type: EXPERIMENTAL
Intervention: Funding by both panels
Number of subjects: 60
Study 26004515 — intervention group
Group type: EXPERIMENTAL
Intervention: Not funded by both panels
Number of subjects: 60
Study 26004515 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall agreement
Number of subjects: 60
Study 26004515 — intervention group
Group type: EXPERIMENTAL
Intervention: Chance-adjusted agreement
Number of subjects: 60
Study 25363153 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component school-based weight management programme
Number of subjects: 0
Study 25363153 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 0
Study 22546597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 1642
Study 22546597 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of interviews
Number of subjects: 1642
Study 20516432 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin plus pegylated liposomal doxorubicin (PLD)
Number of subjects: 672
Study 20516432 — intervention group
Group type: COMPARATOR
Intervention: PLD alone
Number of subjects: 672
Study 20516432 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin plus PLD
Number of subjects: 672
Study 20516432 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin plus PLD (platinum-sensitive patients)
Number of subjects: 672
Study 20516432 — intervention group
Group type: COMPARATOR
Intervention: PLD alone (platinum-sensitive patients)
Number of subjects: 672
Study 18936423 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestroke physical activity in the top quartile
Number of subjects: 265
Study 18936423 — intervention group
Group type: COMPARATOR
Intervention: Control group (lowest quartile of physical activity)
Number of subjects: 265
Study 16082837 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion therapy including solutions of colloids and crystalloids (n=43)
Number of subjects: 71
Study 16082837 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular hydroxyethyl starch in addition to colloids and crystalloids
Number of subjects: 71
Study 12584787 — intervention group
Group type: EXPERIMENTAL
Intervention: Folium Ginkgo extract (FGE) 15 mg/kg.d for 7-8 days
Number of subjects: 30
Study 12584787 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment only)
Number of subjects: 30
Study 10721681 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 to 30 mg per day)
Number of subjects: 475
Study 10721681 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 to 15 mg per day)
Number of subjects: 475
Study 10721681 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 to 60 mg per day)
Number of subjects: 475
Study 10721681 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (60 to 90 mg per day)
Number of subjects: 475
Study 10721681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 8957146 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help attendance
Number of subjects: 519
Study 8957146 — intervention group
Group type: COMPARATOR
Intervention: Non-attenders
Number of subjects: 519
Study 8957146 — intervention group
Group type: COMPARATOR
Intervention: Non-participating attenders
Number of subjects: 519
Study 1493669 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg three times/day)
Number of subjects: 26
Study 1493669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 4014126 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care (intensive treatment group)
Number of subjects: 2376